Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Julphar
Cipla
Daiichi Sankyo
Dow
Colorcon
UBS
Chubb
Healthtrust
Teva

Generated: January 22, 2018

DrugPatentWatch Database Preview

Gemifloxacin mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for gemifloxacin mesylate and what is the scope of gemifloxacin mesylate freedom to operate?

Gemifloxacin mesylate
is the generic ingredient in two branded drugs marketed by Lg Chem Ltd and Orchid Hlthcare, and is included in two NDAs. There are seven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Gemifloxacin mesylate has ninety-one patent family members in forty countries.

There are two drug master file entries for gemifloxacin mesylate. Two suppliers are listed for this compound.
Summary for gemifloxacin mesylate
Pharmacology for gemifloxacin mesylate
Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

US Patents and Regulatory Information for gemifloxacin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Orchid Hlthcare GEMIFLOXACIN MESYLATE gemifloxacin mesylate TABLET;ORAL 090466-001 Jun 15, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for gemifloxacin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 ➤ Subscribe ➤ Subscribe
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for gemifloxacin mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,595,328 Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria ➤ Subscribe
7,700,617 Salt of naphthyridine carboxylic acid derivative ➤ Subscribe
6,279,257 Flush mounting security frames and hardware ➤ Subscribe
5,869,670 7-(4-aminomethyl-3-me thyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8 -naphthyridine-3-carboxylic acid and the process for the preparation thereof ➤ Subscribe
6,938,154 System, method and article of manufacture for a cryptographic key infrastructure for networked devices ➤ Subscribe
5,962,468 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1- cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1, 8-naphthyridine-3-carboxylic acid and the process for the preparation thereof ➤ Subscribe
5,633,262 Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof ➤ Subscribe
5,698,570 Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime)pyrrolidine substituent and processes for preparing thereof ➤ Subscribe
5,840,916 Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituent and processes for preparing thereof ➤ Subscribe
6,659,418 Positioning & locking hanging system ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for gemifloxacin mesylate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Cantor Fitzgerald
Deloitte
McKesson
Medtronic
Julphar
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot